Deltec Asset Management LLC Invests $690,000 in Alimera Sciences, Inc. (NASDAQ:ALIM)

Deltec Asset Management LLC acquired a new position in Alimera Sciences, Inc. (NASDAQ:ALIM) in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 124,169 shares of the biopharmaceutical company’s stock, valued at approximately $690,000. Deltec Asset Management LLC owned approximately 0.24% of Alimera Sciences at the end of the most recent quarter.

Other hedge funds have also recently made changes to their positions in the company. Fifth Lane Capital LP bought a new stake in Alimera Sciences in the 1st quarter valued at about $83,000. Hillsdale Investment Management Inc. bought a new stake in Alimera Sciences in the 1st quarter valued at about $169,000. Ancora Advisors LLC bought a new stake in Alimera Sciences in the 1st quarter valued at about $915,000. Finally, Vanguard Group Inc. increased its position in Alimera Sciences by 61.1% in the 1st quarter. Vanguard Group Inc. now owns 1,045,460 shares of the biopharmaceutical company’s stock valued at $4,077,000 after buying an additional 396,506 shares in the last quarter. 99.83% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on the company. StockNews.com assumed coverage on Alimera Sciences in a research note on Tuesday. They set a “hold” rating for the company. Alliance Global Partners reiterated a “neutral” rating on shares of Alimera Sciences in a research note on Tuesday, June 25th. HC Wainwright downgraded Alimera Sciences from a “buy” rating to a “neutral” rating and set a $6.00 price target for the company. in a research note on Tuesday, June 25th. Finally, Maxim Group reaffirmed a “hold” rating on shares of Alimera Sciences in a report on Tuesday, June 25th.

Alimera Sciences Stock Performance

Shares of ALIM stock traded down $0.01 on Wednesday, hitting $5.59. 64,304 shares of the stock were exchanged, compared to its average volume of 209,006. The company has a current ratio of 2.62, a quick ratio of 2.51 and a debt-to-equity ratio of 1.71. The firm has a market capitalization of $292.85 million, a PE ratio of -3.56 and a beta of 1.28. Alimera Sciences, Inc. has a one year low of $2.61 and a one year high of $5.65. The firm’s 50 day moving average is $4.91 and its two-hundred day moving average is $4.06.

Alimera Sciences (NASDAQ:ALIM) last issued its quarterly earnings data on Tuesday, August 6th. The biopharmaceutical company reported ($0.06) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.02). The company had revenue of $27.00 million for the quarter, compared to analysts’ expectations of $25.76 million. Alimera Sciences had a negative return on equity of 53.49% and a negative net margin of 23.74%. Sell-side analysts expect that Alimera Sciences, Inc. will post -0.13 earnings per share for the current fiscal year.

Alimera Sciences Profile

Alimera Sciences, Inc, a pharmaceutical company, develops and commercializes prescription ophthalmic retinal pharmaceuticals. It operates through United States, International, and Operating Cost segments. The company offers ILUVIEN, a fluocinolone acetonide intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye (NIU-PS).